Current clinical use of intravenous fosfomycin in ICU patients in two European countries-Reference-Cited by-同舟云学术

Current clinical use of intravenous fosfomycin in ICU patients in two European countries

Published:2019-06-12 Issue:5 Volume:47 Page:827-836
ISSN:0300-8126
Container-title:Infection
language:en
Short-container-title:Infection

Author:

Putensen C.,Ellger B.,Sakka S. G.,Weyland A.,Schmidt K.,Zoller M.,Weiler N.,Kindgen-Milles D.,Jaschinski U.,Weile J.,Lindau S.,Kieninger M.,Faltlhauser A.,Jung N.,Teschendorf P.,Adamzik M.,Gründling M.,Wahlers T.,Gerlach H.,Litty F.-A.^ORCID

Funder

InfectoPharm und Consilium GmbH

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s15010-019-01323-4.pdf

Reference45 articles.

1. Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, Miller TW, Chaiet L, Kahan FM, Foltz EL, Woodruff HB, Mata JM, Hernandez S, Mochales S. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science. 1969;166:122–3.

2. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974;235:364–86.

3. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10:43–50.

4. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Invest Drugs. 2009;18:921–44.

5. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29:321–47.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature;Journal of Antimicrobial Chemotherapy;2024-08-31

2. Intravenous fosfomycin indications and treatment outcomes in pediatric usage: analysis from a single center in Turkey;Journal of Tropical Pediatrics;2024-08-10

3. Adverse events during intravenous fosfomycin therapy in a real-life scenario. Risk factors and the potential role of therapeutic drug monitoring;BMC Infectious Diseases;2024-06-28

4. Effect of fosfomycin-induced hypernatremia on patients’ hospital stay length and survival;Irish Journal of Medical Science (1971 -);2024-05-20

5. Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections;Journal of Antimicrobial Chemotherapy;2024-04-10